Picture loading failed.

Anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cadonilimab (AK104) is a novel, potential next-generation,first-in-classbi-specificPD-1/CTLA-4immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-088-1mg 1mg Inquiry
GMP-Bios-ab-088-10mg 10mg Inquiry
GMP-Bios-ab-088-100mg 100mg Inquiry
GMP-Bios-ab-088-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv, Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody)
INN Name Cadonilimab
TargetPD-1;CTLA-4
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesAkeso Biopharma
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma
Conditions Discontinuedna
Development Techna